News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ligand Pharmaceuticals Inc. (LGND) Announces Positive Preclinical Data on IRAK4 Program at the 2011 American College of Rheumatology Annual Scientific Meeting


11/7/2011 8:33:02 AM

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that data from preclinical studies on its Interleukin-1 Receptor Associated Kinase-4 (IRAK4) program was featured in an oral presentation today at the 2011 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP) in Chicago. IRAK4 is a protein kinase involved in immune and inflammatory signaling and has become a high priority novel target for drug development in the areas of oncology and inflammation.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES